U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 1 Colon Perforation, CTCAE

MedGen UID:
284642
•Concept ID:
C1556606
•
Finding

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 1 Colon Perforation, CTCAE

Recent clinical studies

Etiology

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK)
Cancer Immunol Immunother 2021 May;70(5):1255-1262. Epub 2020 Nov 1 doi: 10.1007/s00262-020-02757-8. PMID: 33130956Free PMC Article
Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
Barney BM, Olivier KR, Macdonald OK, Fong de Los Santos LE, Miller RC, Haddock MG
Am J Clin Oncol 2012 Dec;35(6):537-42. doi: 10.1097/COC.0b013e31821f876a. PMID: 21659830

Therapy

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK)
Cancer Immunol Immunother 2021 May;70(5):1255-1262. Epub 2020 Nov 1 doi: 10.1007/s00262-020-02757-8. PMID: 33130956Free PMC Article
Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
Barney BM, Olivier KR, Macdonald OK, Fong de Los Santos LE, Miller RC, Haddock MG
Am J Clin Oncol 2012 Dec;35(6):537-42. doi: 10.1097/COC.0b013e31821f876a. PMID: 21659830

Clinical prediction guides

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK)
Cancer Immunol Immunother 2021 May;70(5):1255-1262. Epub 2020 Nov 1 doi: 10.1007/s00262-020-02757-8. PMID: 33130956Free PMC Article

Supplemental Content

Table of contents

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...